Clinical Cancer Research, Vol 2, Issue 5 889-895, Copyright © 1996 by American Association for Cancer Research

ARTICLES

Androgen and glucocorticoid receptors in the stroma and epithelium of prostatic hyperplasia and carcinoma

JL Mohler, Y Chen, K Hamil, SH Hall, JA Cidlowski, EM Wilson, FS French and M Sar
Departments of Surgery, University of North Carolina-Lineberger Comprehensive Cancer Center, Chapel Hill, 27599, USA.

Differences in stromal and epithelial cell staining for androgen and glucocorticoid receptors (ARs and GRs) were investigated in 20 patients with clinically localized prostatic carcinoma treated by radical prostatectomy. Sections of benign prostatic hyperplasia and prostatic carcinoma from each patient were stained with antibodies to AR and GR using an avidin-biotin peroxidase technique. The specificity of the GR immunoreactivity was established in benign prostatic hyperplasia and prostatic carcinoma by immunohistochemistry using the GR antibody absorbed with synthetic peptide and Western blotting. Nuclear staining intensity and percentage of nuclei stained were summed to obtain AR and GR immunostaining scores. AR staining of prostatic carcinoma epithelial [103 +/- 58 (SD)] and stromal (126 +/- 48) nuclei was less than in benign prostatic hyperplasia (142 +/- 47 and 169 +/- 56; paired Student's t tests, P = 0.02 and P = 0.01); however, no difference in staining intensity occurred between stroma and epithelium in either tissue type. GR stained intensely in stromal cells from benign prostatic hyperplasia (189 +/- 50) and prostatic carcinoma (163 +/- 60). However, prostatic carcinoma epithelial cells (34 +/- 57) had low levels of glucocorticoid receptor staining (P < 10(-7)), and benign prostatic hyperplasia epithelium (74 +/- 51) was intermediate. In most patients, GR could not be detected in nuclei of prostatic carcinoma epithelial cells but was undiminished in stromal cell nuclei. There was no relationship by multivariate regression analysis between AR or GR staining and age, serum prostate-specific antigen, Gleason grade, or pathological stage. In comparison with AR, the greater variability of GR staining in epithelium versus stroma of prostatic carcinoma warrants further study of GR, particularly in the area of stromal-epithelial interaction.

This article has been cited by other articles:

				A. Godoy, A. Watts, P. Sotomayor, V. P. Montecinos, W. J. Huss, S. A. Onate, and G. J. Smith Androgen Receptor Is Causally Involved in the Homeostasis of the Human Prostate Endothelial Cell Endocrinology, June 1, 2008; 149(6): 2959 - 2969. [Abstract] [Full Text] [PDF]

				S. D Conzen Environmental Stress and the Neuroendocrine Response: Is There a Cancer Connection? Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 255 - 262. [Abstract] [Full Text] [PDF]

				J. E. Tillman, J. Yuan, G. Gu, L. Fazli, R. Ghosh, A. S. Flynt, M. Gleave, P. S. Rennie, and S. Kasper DJ-1 Binds Androgen Receptor Directly and Mediates Its Activity in Hormonally Treated Prostate Cancer Cells Cancer Res., May 15, 2007; 67(10): 4630 - 4637. [Abstract] [Full Text] [PDF]

				Z. Yang, Y.-J. Chang, H. Miyamoto, S. Yeh, J. L. Yao, P. A. di Sant'Agnese, M.-Y. Tsai, and C. Chang Suppression of Androgen Receptor Transactivation and Prostate Cancer Cell Growth by Heterogeneous Nuclear Ribonucleoprotein A1 via Interaction with Androgen Receptor Coregulator ARA54 Endocrinology, March 1, 2007; 148(3): 1340 - 1349. [Abstract] [Full Text] [PDF]

				Z. Yang, Y.-J. Chang, H. Miyamoto, J. Ni, Y. Niu, Z. Chen, Y.-L. Chen, J. L. Yao, P. A. di Sant'Agnese, and C. Chang Transgelin Functions as a Suppressor via Inhibition of ARA54-Enhanced Androgen Receptor Transactivation and Prostate Cancer Cell Growth Mol. Endocrinol., February 1, 2007; 21(2): 343 - 358. [Abstract] [Full Text] [PDF]

				P. Cano, A. Godoy, R. Escamilla, R. Dhir, and S. A. Onate Stromal-Epithelial Cell Interactions and Androgen Receptor-Coregulator Recruitment Is Altered in the Tissue Microenvironment of Prostate Cancer Cancer Res., January 15, 2007; 67(2): 511 - 519. [Abstract] [Full Text] [PDF]

				N. Ismaili, R. Blind, and M. J. Garabedian Stabilization of the Unliganded Glucocorticoid Receptor by TSG101 J. Biol. Chem., March 25, 2005; 280(12): 11120 - 11126. [Abstract] [Full Text] [PDF]

				C. A. Heinlein and C. Chang Androgen Receptor in Prostate Cancer Endocr. Rev., April 1, 2004; 25(2): 276 - 308. [Abstract] [Full Text] [PDF]

				I. V. Scholz, N. Cengic, B. Goke, J. C. Morris, and C. Spitzweg Dexamethasone Enhances the Cytotoxic Effect of Radioiodine Therapy in Prostate Cancer Cells Expressing the Sodium Iodide Symporter J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1108 - 1116. [Abstract] [Full Text] [PDF]

				K. Nishimura, N. Nonomura, E. Satoh, Y. Harada, M. Nakayama, T. Tokizane, T. Fukui, Y. Ono, H. Inoue, M. Shin, et al. Potential Mechanism for the Effects of Dexamethasone on Growth of Androgen-Independent Prostate Cancer J Natl Cancer Inst, November 21, 2001; 93(22): 1739 - 1746. [Abstract] [Full Text] [PDF]

				M.-F. Lin, T.-C. Meng, P. S. Rao, C. Chang, A. H. Schonthal, and F.-F. Lin Expression of Human Prostatic Acid Phosphatase Correlates with Androgen-stimulated Cell Proliferation in Prostate Cancer Cell Lines J. Biol. Chem., March 6, 1998; 273(10): 5939 - 5947. [Abstract] [Full Text] [PDF]

				C. B. J. M. Cleutjens, K. Steketee, C. C. E. M. van Eekelen, J. A. G. M. van der Korput, A. O. Brinkmann, and J. Trapman Both Androgen Receptor and Glucocorticoid Receptor Are Able to Induce Prostate-Specific Antigen Expression, but Differ in Their Growth-Stimulating Properties of LNCaP Cells Endocrinology, December 1, 1997; 138(12): 5293 - 5300. [Abstract] [Full Text] [PDF]